Exelixis | EXEL - Ordinary Share Capital


Exelixis reported $268.1M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Akebia Therapeutics USD 2K 0 Mar/2025
Amgen USD 539M 1000K Dec/2025
AstraZeneca USD 1.55B 206K Dec/2025
Bayer EUR 982.42M 0 Dec/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cytokinetics USD 122.26M 145K Dec/2025
Eisai JPY 282.11M 1000 Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Esperion Therapeutics USD 112K 11K Sep/2023
Exelixis USD 268.1M 2.03M Sep/2025
Genmab DKK 10M 56M Mar/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.94B 23.4M Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
Puma Biotechnology USD 5K 0 Jun/2024
Takeda JPY 1.58B 2K Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Xencor USD 71.87M 529K Dec/2025